Professor Kim conducted a comparative analysis of the effects of 'RCI001' and '1% prednisolone (PDE steroid),' currently the most potent topical anti-inflammatory agent in use, in an animal model of ocular chemical burn.
The research results revealed that 'RCI001' was superior in efficacy and had fewer side effects compared to the existing steroid drug.
Specifically, 'RCI001' outperformed the steroid in corneal epithelial defect and transparency recovery, infiltration of inflammatory cells within corneal tissue, 'inflammatory cytokines' that cause excessive inflammation on the ocular surface, and 'oxidative stress markers' indicating cell damage caused by reactive oxygen species in the body.
In contrast, elevated intraocular pressure — a representative side effect commonly found with steroid drugs — was not observed with 'RCI001.'
Professor Kim's research was published under the title 'Comparison of therapeutic effects between topical 8‑oxo‑2′‑deoxyguanosine and prednisolone in a rabbit model of acute ocular chemical injury,' drawing significant attention from the academic community for providing a scientific basis for the potential of RCI001 as a next-generation ophthalmic treatment.